Nirav Gandhi, MD
Nephrology · Anaheim, CANPI 1649263252
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 27.2% of the total.
Across 69 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$736
- AstraZeneca$653
- Akebia Therapeutics Inc$347
- Ardelyx, Inc.$145
- Amgen$116
- Bayer$104
- plus $612 from 12 others
Across 597 payments — averaging $2984.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1M
- Akebia Therapeutics Inc$553K
- GSK$208K
- Boehringer Ingelheim International GmbH$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
What the payments were for
- Food & beverage$2,712100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $736 |
| AstraZeneca(2 entities) | 11 | $653 |
| Akebia Therapeutics Inc | 7 | $347 |
| Ardelyx, Inc. | 7 | $145 |
| Amgen | 5 | $116 |
| Bayer | 4 | $104 |
| Travere Therapeutics, Inc. | 1 | $95 |
| Vifor Pharma, Inc. | 4 | $90 |
| Baxter Healthcare | 1 | $72 |
| Boehringer Ingelheim | 2 | $56 |
| Fresenius USA Marketing, Inc. | 1 | $56 |
| Aurinia Pharma U.S., Inc. | 3 | $55 |
| Apellis Pharmaceuticals, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $37 |
| Novartis | 1 | $33 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Nxstage Medical, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,712 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 23 | $84,644 |
| FarxigaDapagliflozin Propanediol | 48 | $64,325 |
| LokelmaSodium Zirconium Cyclosilicate | 50 | $44,318 |
| JardianceEmpagliflozin | 34 | $32,543 |
| ProcritEpoetin Alfa | 24 | $22,798 |
| JanuviaSitagliptin Phosphate | 24 | $19,941 |
| Sevelamer Carbonate | 27 | $9,305 |
| Calcium Acetate | 74 | $5,807 |
| Demeclocycline Hcl | 17 | $5,771 |
| Tacrolimus | 19 | $3,270 |
| Furosemide | 304 | $1,869 |
| Tamsulosin Hcl | 81 | $932 |
| Metoprolol Succinate | 53 | $920 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $826 |
| Calcitriol | 35 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $653 | $108,64398 claims |
| Fresenius USA Marketing, Inc.Velphoro | $56 | $84,64423 claims |
| Boehringer IngelheimJardiance | $56 | $32,54334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.
Other nephrology in Anaheim
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.